米氮平与氯丙米嗪治疗抑郁症伴焦虑临床评价  

Clinical Evaluation on Mirtazapine and Clomipraminein in the Treatment of Depressive Disorder Associated with Anxiety.

作　　者：王春阳[1] 郭平[1] 

机构地区：[1]中国.河南驻马店市精神病医院,463000

出　　处：《中国健康心理学杂志》2007年第11期966-967,共2页China Journal of Health Psychology

摘　　要：目的比较米氮平与氟丙米嗪对抑郁症伴焦虑的疗效及其安全性。方法将111例抑郁症分为两组。米氮平组56例，口服米氮平30～45mg，1次／日；氯丙米嗪组55例，口服氯丙米嗪100～200mg，2次／日；均6周为1个疗程。结果对抑郁症状的治疗，米氮平组显效率73．2％，氯丙米嗪组显效率67．3％，疗效差异无显著意义（P〉0．05）；对焦虑症状的治疗，米氮平组显效率78．8％，氯丙米嗪组显效率43．6％，疗效差异有显著性（P〈0．05）。整体药物不良反应发生率两组相当。结论米氮平与氯丙米嗪是安全有效的治疗抑郁症的药物，但抗焦虑作用米氮平优于氯丙米嗪。Objective To compare the clinical effects and adverse reactions of mirtazapine and clomipramine in the treatment of depression associated with anxiety, Methods One hundred and eleven patients depression associated with anxiety were divided into 2 groups： Fifty-six patients （M30, F2G, age 39.4±13.7） were treated with mirtazapine, 30～45mg, po, qd for 6wk; fifty-five patients （M29, F26, age 40.2±12.6） were treated with clomipramine, 10～200mg, po, bid for 6wk. Results The marked effective rate of mirtazapine group and clomipramine group were 73.2% and 67.3% （P〉0.05） in treating depression symptomy but the marked effective rate of mirtazapine group and clomipramine group were 78.8% and 43.6% （P〈0. 05） in treating anxiety symptoms. The adverse reactions in mirtazapine group and clomipramine group should no significant difference. Conclusion Mirtazapine and clomipramineis a safe and effective drug for treatment of depression, but mirtazapine is superior to elomipraminein reducing anxiety symptoms.

关 键 词：米氮平 氯丙米嗪 抑郁症 焦虑 临床评价 

分 类 号：R971[医药卫生—药品]